A quick test to determine drug resistance in tuberculosis
A Rapid Phenotypic Drug Susceptibility Testing System for Tuberculosis
This study is working on a new, quick test called Tre-DST that helps doctors find out if tuberculosis is resistant to certain drugs, so patients can get the right treatment faster, especially in places where resources are limited.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10777490 on NIH RePORTER |
What this research studies
This research focuses on developing a rapid phenotypic drug susceptibility testing system for tuberculosis (TB) to identify drug-resistant strains quickly. The proposed test, called Tre-DST, utilizes novel trehalose probes to provide accurate results in a cost-effective manner, particularly beneficial for resource-limited settings. By enabling faster diagnosis of drug resistance, the research aims to facilitate timely treatment for patients, ultimately improving care outcomes. The approach addresses the limitations of current testing methods, which often take too long and are expensive.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, particularly those suspected of having drug-resistant strains.
Not a fit: Patients who do not have tuberculosis or those with non-infectious conditions will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to quicker and more accurate diagnosis of drug-resistant tuberculosis, allowing for timely and effective treatment.
How similar studies have performed: Previous research has shown promise in developing rapid testing methods for infectious diseases, indicating potential success for this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kamariza, Mireille — University of California Los Angeles
- Study coordinator: Kamariza, Mireille
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.